Overview ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis Status: RECRUITING Trial end date: 2026-10-01 Target enrollment: Participant gender: Summary This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.Phase: PHASE2 Details Lead Sponsor: Aclaris Therapeutics, Inc.